Minocycline in acne vulgaris: Benefits and risks

American Journal of Clinical Dermatology

Volumn 11, Issue 5, 2010, Pages 327-341

  Ochsendorf, Falk ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYL PEROXIDE; CLINDAMYCIN; CYPROTERONE ACETATE; DOXYCYCLINE; ERYTHROMYCIN; ETHINYLESTRADIOL; FUSIDIC ACID; GLUCONATE ZINC; ISOTRETINOIN; LYMECYCLINE; MACROLIDE; MINOCYCLINE; OXYTETRACYCLINE; PLACEBO; TAZAROTENE; TETRACYCLINE; ANTIINFECTIVE AGENT;

ACNE; ACNE VULGARIS; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE HEPATITIS; BULLOUS DERMATITIS; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; CONFLUENT AND RETICULATED PAPILLOMATOSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIARRHEA; DIZZINESS; DRESS SYNDROME; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS EROSION; FLATULENCE; GASTRITIS; HUMAN; HYPERPIGMENTATION; INTERMETHOD COMPARISON; LEPROSY; LIVER FAILURE; LIVER TOXICITY; LONG TERM CARE; LUPUS LIKE SYNDROME; LYMPHOMATOID PAPULOSIS; MALARIA; MYCOBACTERIOSIS; NAUSEA; NECROTIZING ARTERITIS; NEUROPATHIC PAIN; NONHUMAN; PANCREATITIS; PEPTIC ULCER; PHOTOTOXICITY; PNEUMONIA; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PRURIGO; PSEUDOMEMBRANOUS COLITIS; PYODERMA GANGRENOSUM; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; TISSUE DISTRIBUTION; VAGINA CANDIDIASIS; VERTIGO; ECONOMICS; RISK ASSESSMENT; TREATMENT OUTCOME;

ACNE VULGARIS; ANTI-BACTERIAL AGENTS; HUMANS; MINOCYCLINE; RISK ASSESSMENT; TETRACYCLINE RESISTANCE; TREATMENT OUTCOME;

EID: 77954794472     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11319280-000000000-00000     Document Type: Review

References (111)

1. Laugier P, Daguet J. Acne conglobata successfully treated with aureomycin. Bull Soc Fr Dermatol Syphiligr 1951 Jan-Feb; 58 (1): 74-75.
2. ChemBlink. Database of chemicals from around the world [online]. Available from URL: http://www.chemblink.com/name/m57.htm [Accessed 2010 May 26].
3. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64 (1): 63-88.
4. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006 Feb; 54 (2): 258-265.
5. Eady EA, Cove JH. Is acne an infection of blocked pilosebaceous follicles? Implications for antimicrobial treatment. Am J Clin Dermatol 2000; 1: 201-209.
6. Eady EA, Cove JH, Holland KT, et al. Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated acne patients. Br J Dermatol 1990; 122: 233-244.
7. Eady EA, Jones CE, Gardner KJ, et al. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline. Br J Dermatol 1993; 128: 556-560.
8. Hubbell CG, Hobbs ER, Rist T, et al. Efficacy of minocycline compared with tetracycline in treatment of acne vulgaris. Arch Dermatol 1982; 118 (12): 989-992.
9. Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983 Jan; 8 (1): 41-45.
10. Brown SK., Shalita AR. Acne vulgaris. Lancet 1998; 351 (9119): 1871-1876.
11. McManus P, Iheanacho I. Don't useminocycline as first line oral antibiotic in acne. Br Med J 2007 Jan 20; 334 (7585): 154.
12. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006 Aug; 58 (2): 256-265.
13. Dreno B, Bettoli V, Ochsendorf F, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol 2004 Nov-Dec; 14 (6): 391-399.
14. Bernier C, Dreno B.Minocycline. AnnDermatol Venereol 2001 May; 128 (5): 627-637.
15. Chopra I, Roberts M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65: 232-260.
16. Celerier P, Litoux P,Dreno B. In vitro modulation of epidermal inflammatory cytokines (IL-1 alpha, IL-6,TNF alpha) by minocycline. Arch Dermatol Res 1996 Jun; 288 (7): 411-414.
17. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dental Res 1998 Nov; 12 (2): 12-26.
18. Jain A, Sangal L, Basal E, et al. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of 338 chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J 2002; 8: 2.
19. Alarcon GS. Tetracyclines for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 2000 Jul; 9 (7): 1491-1498.
20. Miyazaki E, Ando M, Fukami T, et al. Minocycline for the treatment of sarcoidosis: is themechanism of action immunomodulating or antimicrobial effect? Clin Rheumatol 2008 Sep; 27 (9): 1195-1197.
21. Rempe S, Hayden JM, Robbins RA, et al. Tetracyclines and pulmonary inflammation. Endocr Metab Immune Disord Drug Targets 2007 Dec; 7 (4): 232-236.
22. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res 2009 Jan 23; 196 (2): 168-179.
23. Padi SS, Kulkarni SK. Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms. Eur J Pharmacol 2008 Dec 28; 601 (1-3): 79-87.
24. Buller KM, Carty ML, Reinebrant HE, et al. Minocycline: a neuroprotective agent for hypoxic-ischemic brain injury in the neonate? J Neurosci Res 2009 Feb 15; 87 (3): 599-608.
25. Miyaoka T, Yasukawa R, Yasuda H, et al. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol 2008 Sep-Oct; 31 (5): 287-292.
26. Romero-Perez D, Fricovsky E, Yamasaki KG, et al. Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. JAmColl Cardiol 2008 Sep 23; 52 (13): 1086-1094.
27. Lehmann HP, Andrews JS, Robinson KA, et al. Management of acne (evidence report/technology assessment no. 17 (prepared by Johns Hopkins Evidence-based Practice Center under contract no. 290-97-006): HRQ Publication No. 01-E019. Rockville (MD): Agency for Healthcare Research and Quality, 2001.
28. Ochsendorf F. Systemic antibiotic therapy of acne vulgaris. JDtsch Dermatol Ges 2006 Oct; 4 (10): 828-841.
29. Pierard-Franchimont C, Goffin V, Arrese JE, et al. Lymecycline and minocycline in inflammatory acne: a randomized, double-blind intent-to-treat study on clinical and in vivo antibacterial efficacy. Skin Pharmacol Appl Skin Physiol 2002; 15 (2): 112-119.
30. Layton AM, Hughes BR, Hull SM, et al. Seborrhoea: an indicator for poor clinical response in acne patients treated with antibiotics. Clin ExpDermatol 1992; 17: 173-175.
31. Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003; 4 (12): 813-831.
32. [No authors listed]. Ad hoc committee report: systemic antibiotics for treatment of acne vulgaris: efficacy and safety. Arch Dermatol 1975 Dec; 111 (12): 1630-1636.
33. Lehmann HP, Robinson KA, Andrews JS, et al. Acne therapy: a methodologic review. J Am Acad Dermatol 2002; 47: 231-240.
34. Garner SE, Eady EA, Popescu C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2003; (1): CD002086.
35. Garner SE, Eady EA, Popescu C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2000; (2): CD002086.
36. National Library of Medicine. Management of acne. Vol 1. Evidence report and appendixes [online]. Available from URL: http://www.ncbi.nlm.nih. gov/books/bv.fcgi?rid=hstat1.chapter.24841 [Accessed 2010 May 26].
37. National Library of Medicine. Management of acne. Vol 2. Evidence tables and bibliography [online]. Available from URL: http://www.ncbi.nlm.nih. gov/books/bv.fcgi?rid=hstat1.chapter.26118 [Accessed 2010 May 26].
38. Dreno B, Moyse D, Alirezai M, et al. Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Dermatology 2001; 203 (2): 135-140.
39. Gollnick HP, Graupe K, Zaumseil RP. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol 2001; 11 (6): 538-544.
40. Bossuyt L, Bosschaert J, Richert B, et al. Lymecycline in the treatment of acne: an efficacious, safe and cost-effective alternative to minocycline. Eur J Dermatol 2003; 13 (2): 130-135.
41. Leyden J, Bergfeld W, Drake L, et al. A systemic type I 5-alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris. JAmAcad Dermatol 2004; 50 (3): 443-447.
42. Ozolins M, Eady EA, Avery A, et al. Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. Health Technol Assess 2005 Jan; 9 (1): iii-212.
43. Stewart DM, Torok HM, Weiss JS, et al. Dose-ranging efficacy of new oncedaily extended-release minocycline for acne vulgaris. Cutis 2006 Oct; 78 (4 Suppl.): 11-20.
44. Fleischer Jr AB, Dinehart S, Stough D, et al. Safety and efficacy of a new extended-release formulation of minocycline. Cutis 2006 Oct; 78 (4 Suppl.): 21-31.
45. Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximabassociated acne-like eruption. J Clin Oncol 2007 Dec 1; 25 (34): 5390-5396.
46. Samuelson JS. An accurate photographic method for grading acne: initial use in a double-blind clinical comparison of minocycline and tetracycline. J Am Acad Dermatol 1985; 12 (3): 461-467.
47. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001 Feb; 144 (2): 339-346.
48. Simonart T, Dramaix M, De Maertelaer V. Efficacy of tetracyclines in the treatment of acne vulgaris: a review. Br J Dermatol 2008 Feb; 158 (2): 208-216.
49. Bjellerup M, Ljunggren B. Differences in phototoxic potency should be considered when tetracyclines are prescribed during summer-time: a study on doxycycline and lymecycline in human volunteers, using an objective method for recording erythema. Br J Dermatol 1994; 130: 356-360.
50. Oriel JD, Waterworth PM. Effects of minocycline and tetracycline on the vaginal yeast flora. J Clin Pathol 1975; 28: 403-406.
51. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005 Sep; 27 (9): 1329-1342.
52. Sturkenboom MC, Meier CR, Jick H, et al. Minocycline and lupus-like syndrome in acne patients. Arch Intern Med 1999; 159: 493-497.
53. Piette AM, Ramanoelina J, Gepner P, et al. Systemic reaction induced my minocycline treatment: a report of four patients and a review of the literature. Rev Med Interne 1999 Oct; 20 (10): 869-874.
54. Schlienger RG, Bircher AJ, Meier CR. Minocycine-induced lupus: a systematic review. Dermatology 2000; 200: 223-231.
55. Barbagelata Lopez C, Otero Palleiro MM, Seoane Gonzalez B, et al. Minocycline-induced hypersensitivity pneumonitis [letter]. Med Clin (Barc) 2007 Jan 20; 128 (2): 79.
56. Ahmed F,Kelsey PR, Shariff N. Lupus syndrome with neutropenia following minocycline therapy: a case report. Int J Lab Hematol 2008 Dec; 30 (6): 543-545.
57. El-Hallak M, Giani T, Yeniay BS, et al. Chronic minocycline-induced autoimmunity in children. J Pediatr 2008 Sep; 153 (3): 314-319.
58. Fanning WL, Dieter WG, Sofferman RA. Side effects of minocycline: a double blind study. Antimicrob Agents Chemother 1977; 11: 712-717.
59. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 1996; 134: 693-695.
60. [No authors listed]. Fewer adverse effects with doxycycline than with minocycline. Prescrire Int 2009 Oct; 18 (103): 213.
61. Layton AM, Cunfliffe W. Phototoxic eruptions due to doxycycline: A doserelated phenomenon. Clin Exp Dermatol 1993; 18: 425-427.
62. Lim DS, Murphy GM. High-level ultraviolet A photoprotection is needed to prevent doxycycline phototoxicity: lessons learned in East Timor. Br J Dermatol 2003; 149: 213-214.
63. Frost P, Weinstein GD, Gomez EC. Phototoxic potential of minocycline and doxycycline. Arch Dermatol 1972; 105: 681-683.
64. Eisen D, Hakim MD. Minocycline-induced pigmentation: Incidence, prevention and management. Drug Saf 1998 Jun; 18 (6): 431-440.
65. Gordon G, Sparano BM, Iatropoulos MJ. Hyperpigmentation of the skin associated with minocycline therapy. Arch Dermatol 1985 May; 121 (5): 618-623.
66. Basler RS. Minocycline-related hyperpigmentation. Arch Dermatol 1985 May; 121 (5): 606-608.
67. Mouton RW, Jordaan HF, Schneider JW. Anew type ofminocycline-induced cutaneous hyperpigmentation. Clin Exp Dermatol 2004; 29 (1): 8-14.
68. Tanzi EL, Hecker MS. Special selection: minocycline-induced hyperpigmentation of the tongue. Arch Fam Med 2000 Aug; 9 (8): 687-688.
69. Ayangco L, Sheridan PJ.Minocycline-induced staining of torus palatinus and alveolar bone. J Periodontol 2003; 74 (5): 669-671.
70. Swanson JK. Acne treatment may cause appearance of discolored gums [letter]. Dent Today 2003; 22 (9): 36.
71. Pandit S, Hadden W. Black pigmentation of bone due to long-term minocycline use. Surgeon 2004 Aug; 2 (4): 236-237.
72. Treister NS, Magalnick D, Woo SB. Oral mucosal pigmentation secondary to minocycline therapy: report of two cases and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004 Jun; 97 (6): 718-725.
73. Rahman Z, Lazova R, Antaya RJ. Minocycline hyperpigmentation isolated to the subcutaneous fat. J Cutan Pathol 2005 Aug; 32 (7): 516-519.
74. Sanchez AR, Rogers 3rd RS, Sheridan PJ. Tetracycline and other tetracyclinederivative staining of the teeth and oral cavity. Int J Dermatol 2004 Oct; 43 (10): 709-715.
75. Greve B, Schönermark MP, Raulin C. Minocycline-induced hyperpigmentation: treatment with the Q-switched Nd:YAG laser. Lasers Surg Med 1998; 22 (4): 223-227. (Pubitemid 28213376)
76. Knoell KA, Milgraum SS, Kutenplon M. Q-switched ruby laser treatment of minocycline-induced cutaneous hyperpigmentation. Arch Dermatol 1996 Oct; 132 (10): 1251-1253.
77. Tsao H, Busam K, Barnhill RL, et al. Treatment of minocycline-induced hyperpigmentationwith theQ-switched ruby laser. Arch Dermatol 1996 Oct; 132 (10): 1250-1251.
78. Friedman IS, Shelton RM, Phelps RG. Minocycline-induced hyperpigmentation of the tongue: successful treatment with the Q-switched ruby laser. Dermatol Surg 2002 Mar; 28 (3): 205-209.
79. Alster TS, Gupta SN. Minocycline-induced hyperpigmentation treated with a 755-nm Q-switched alexandrite laser. Dermatol Surg 2004 Sep; 30 (9): 1201-1204.
80. Green D, Friedman KJ. Treatment of minocycline-induced cutaneous pigmentation with the Q-switched Alexandrite laser and a review of the literature. J Am Acad Dermatol 2001 Feb; 44 (2 Suppl.): 342-347.
81. Izikson L, Anderson RR. Resolution of blue minocycline pigmentation of the face after fractional photothermolysis. Lasers Surg Med 2008 Aug; 40 (6): 399-401.
82. Soung J, Cohen J, Phelps R, et al. Case reports: minocycline-induced hyperpigmentation resolves during oral isotretinoin therapy. J Drugs Dermatol 2007 Dec; 6 (12): 1232-1236.
83. Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther 2007 Oct; 32 (5): 483-487.
84. Boudreaux JP, Hayes DH, Mizrahi S, et al. Fulminant hepatic failure, hepatorenal syndrome, and necrotizing pancreatitis after minocycline hepatotoxicity [letter]. Transplant Proc 1993 Apr; 25 (2): 1873.
85. Ford TJ, Dillon JF.Minocycline hepatitis. Eur J Gastroenterol Hepatol 2008 Aug; 20 (8): 796-799.
86. Lawrenson RA, Seaman HE, Sundstrom A, et al. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf 2000; 23: 333-349.
87. Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum 1999 Jun; 28 (6): 392-397.
88. Brown RJ, Rother KI, Artman H, et al. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. Arch Dermatol 2009 Jan; 145 (1): 63-66.
89. EshkiM, Allanore L, Musette P, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol 2009 Jan; 145 (1): 67-72.
90. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycine, minocycline and doxycycine. Arch Dermatol 1997; 133: 1224-1230.
91. Guillon JM, Joly P, Autran B, et al. Minocycline-induced cell-mediated hypersensitivity pneumonitis. Ann Intern Med 1992 Sep 15; 117 (6): 476-481.
92. Maubec E, Wolkenstein P, Loriot MA, et al. Minocycline-induced DRESS: evidence for accumulation of the culprit drug. Dermatology 2008; 216 (3): 200-204.
93. MacNeil M, Haase DA, Tremaine R, et al. Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline. J Am Acad Dermatol 1997 Feb; 36 (2 Pt 2): 347-350.
94. Culver B, Itkin A, Pischel K. Case report and review of minocyclineinduced cutaneous polyarteritis nodosa. Arthritis Rheum 2005 Jun 15; 53 (3): 468-470.
95. Khan Durani B, Jappe U. Drug-induced Sweet's syndrome in acne caused by different tetracyclines: case report and review of the literature. Br JDermatol 2002; 147 (3): 558-562.
96. Schrodt BJ, Kulp-Shorten CL, Callen JP. Necrotizing vasculitis of the skin and uterine cervix associated with minocycline therapy for acne vulgaris. South Med J 1999 May; 92 (5): 502-504.
97. Dukic R, Derragui A, Geiss S, et al. Minocycline-induced lymphomatoid papulosis [in French]. Rev Med Interne 2004 May; 25 (5): 401-404.
98. Chapman-Davies A, Lazarevic A. Benign intracranial hypertension with minocycline therapy. Clin Exp Optom 2000 Sep; 83 (5): 271-273.
99. Ang ER, Zimmerman JC, Malkin E. Pseudotumor cerebri secondary to minocycline intake. J Am Board Fam Pract 2002 May-Jun; 15 (3): 229-233.
100. Winn BJ, Liao YJ, Horton JC. Intracranial pressure returns to normal about a month after stopping tetracycline antibiotics. Arch Ophthalmol 2007 Aug; 125 (8): 1137-1138.
101. Oprica C, Lofmark S, Lund B, et al. Genetic basis of resistance in Propionibacterium acnes strains isolated from diverse types of infection in different European countries. Anaerobe 2005 Jun; 11 (3): 137-143.
102. Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003; 148 (3): 467-478.
103. Coates P, Vyakrnam S, Eady EA, et al. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol 2002 May; 146 (5): 840-848.
104. Ochsendorf FR. Clinical relevance of antibiotic resistance in acne. G Ital Dermatol Venereol 2006; 141: 183-186.
105. Oprica C, Emtestam L, Hagstromer L, et al. Clinical and microbiological comparisons of isotretinoin vs. tetracycline in acne vulgaris. Acta Derm Venereol 2007; 87 (3): 246-54 340
106. [No authors listed]. Minocycline for acne: an update. Drug Ther Bull 2009; 47 (1): 7-8.
107. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60 (5 Suppl.): S1-50.
108. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139 (4): 459-464.
109. Toossi P, Farshchian M, Malekzad F, et al. Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J Drugs Dermatol 2008 Dec; 7 (12): 1149-1152.
110. Dreno B, Bettoli V, Ochsendorf F, et al. An expert view on the treatment of acne with systemic antibiotics and/or oral isotretinoin in the light of the new European recommendations. Eur J Dermatol 2006 Sep-Oct; 16 (5): 565-571.
111. [No authors listed]. Is minocycline overused in acne? Drug Ther Bull 2006 Aug; 44 (8): 60-62.